Floatz logo

FLUOROURACILUM

Thoracic Cancer

Tango Therapeutics, Inc.Small moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Thoracic Cancer cohort.

Asset / SponsorPhaseRating
Lisinopril
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Lipitor
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Eloxatin
Tango Therapeutics, Inc.
Phase 1/2CC
Rmc-6236
Tango Therapeutics, Inc.
Phase 1/2CC
Pedmark® Sts
University of Arizona
Phase 1/2CC

View all 10 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →